

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - CBER Director Vinay Prasad dared to “say no to drugs”















